{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:53:50Z","timestamp":1793332430024,"version":"4.5.0"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T00:00:00Z","timestamp":1679788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T00:00:00Z","timestamp":1679788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Microbiol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00203-023-03461-8","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T03:16:15Z","timestamp":1679800575000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A computational overview of integrase strand transfer inhibitors (INSTIs) against emerging and evolving drug-resistant HIV-1 integrase mutants"],"prefix":"10.1007","volume":"205","author":[{"given":"Sharif Karim","family":"Sayyed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7784-6889","authenticated-orcid":false,"given":"Marzuqa","family":"Quraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renitta","family":"Jobby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelamegam","family":"Rameshkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagarajan","family":"Kayalvizhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthukalingan","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tareeka","family":"Sonawane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,26]]},"reference":[{"key":"3461_CR1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/435674","author":"AS Abdelhameed","year":"2015","unstructured":"Abdelhameed AS (2015) Insight into the interaction between the HIV-1 integrase inhibitor elvitegravir and bovine serum albumin: a spectroscopic study. J Spectrosc. https:\/\/doi.org\/10.1155\/2015\/435674","journal-title":"J Spectrosc"},{"key":"3461_CR2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02533-18","author":"RK Acosta","year":"2019","unstructured":"Acosta RK, Willkom M, Martin R et al (2019) Resistance analysis of bictegravir-emtricitabine-tenofovir alafenamide in HIV-1 treatment-naive patients through 48 weeks. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.02533-18","journal-title":"Antimicrob Agents Chemother"},{"key":"3461_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1517\/14656566.2012.642865","volume":"13","author":"MO Akanbi","year":"2012","unstructured":"Akanbi MO, Scarci K, Taiwo B, Murphy RL (2012) Combination nucleoside\/nucleotide reverse transcriptase inhibitors. Exp Opin Pharmacother 13:65. https:\/\/doi.org\/10.1517\/14656566.2012.642865","journal-title":"Exp Opin Pharmacother"},{"key":"3461_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000501016","volume":"62","author":"N Alaoui","year":"2019","unstructured":"Alaoui N, El Alaoui MA, El Annaz H et al (2019) HIV-1 integrase resistance among highly antiretroviral experienced patients from Morocco. Intervirology 62:65\u201371. https:\/\/doi.org\/10.1159\/000501016","journal-title":"Intervirology"},{"key":"3461_CR5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/JCPH.1788","volume":"61","author":"G Alavian","year":"2021","unstructured":"Alavian G, Kolahdouzan K, Mortezazadeh M, Torabi ZS (2021) Antiretrovirals for prophylaxis against COVID-19: a comprehensive literature review. J Clin Pharmacol 61:581\u2013590. https:\/\/doi.org\/10.1002\/JCPH.1788","journal-title":"J Clin Pharmacol"},{"key":"3461_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/S12977-017-0360-7","volume":"14","author":"K Anstett","year":"2017","unstructured":"Anstett K, Brenner B, Mesplede T, Wainberg MA (2017) HIV drug resistance against strand transfer integrase inhibitors. Retrovirology 14:36. https:\/\/doi.org\/10.1186\/S12977-017-0360-7","journal-title":"Retrovirology"},{"key":"3461_CR7","doi-asserted-by":"publisher","DOI":"10.5772\/52344","author":"R Arora","year":"2013","unstructured":"Arora R, Tchertanov L (2013) The HIV-1 integrase: modeling and beyond. Integr View Mol Recognit Toxinol. https:\/\/doi.org\/10.5772\/52344","journal-title":"Integr View Mol Recognit Toxinol"},{"key":"3461_CR8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/JMR.2277","volume":"26","author":"R Arora","year":"2013","unstructured":"Arora R, De Beauchene IC, Polanski J et al (2013) Raltegravir flexibility and its impact on recognition by the HIV-1 IN targets. J Mol Recognit 26:383\u2013401. https:\/\/doi.org\/10.1002\/JMR.2277","journal-title":"J Mol Recognit"},{"key":"3461_CR9","unstructured":"Arora R (2013) Molecular mechanism of HIV-1 integrase inhibition by Raltegravir proposed by using of molecular modeling approaches"},{"key":"3461_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.18596\/JOTCSA.478772","volume":"6","author":"N Arslan","year":"2019","unstructured":"Arslan N (2019) Molecular docking study of four chromene derivatives as novel HIV-1 integrase inhibitors. J Turk Chem Soc Sect A Chem 6:133\u2013142. https:\/\/doi.org\/10.18596\/JOTCSA.478772","journal-title":"J Turk Chem Soc Sect A Chem"},{"key":"3461_CR11","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2215\/CJN.02240218","volume":"14","author":"MG Atta","year":"2019","unstructured":"Atta MG, De Seigneux S, Lucas GM (2019) Clinical pharmacology in HIV therapy. Clin J Am Soc Nephrol 14:435. https:\/\/doi.org\/10.2215\/CJN.02240218","journal-title":"Clin J Am Soc Nephrol"},{"key":"3461_CR12","unstructured":"Avert (2020) HIV and AIDS in India. In: Avert. https:\/\/www.avert.org\/professionals\/hiv-around-world\/asia-pacific\/india. Accessed 27 Feb 2022"},{"key":"3461_CR13","doi-asserted-by":"publisher","first-page":"9210","DOI":"10.1128\/JVI.01164-10","volume":"84","author":"T Bar-Magen","year":"2010","unstructured":"Bar-Magen T, Sloan RD, Donahue DA et al (2010) Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol 84:9210. https:\/\/doi.org\/10.1128\/JVI.01164-10","journal-title":"J Virol"},{"key":"3461_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/METABO9050087","author":"NN Besednova","year":"2019","unstructured":"Besednova NN, Zvyagintseva TN, Kuznetsova TA et al (2019) Marine algae metabolites as promising therapeutics for the prevention and treatment of HIV\/AIDS. Metabolites. https:\/\/doi.org\/10.3390\/METABO9050087","journal-title":"Metabolites"},{"key":"3461_CR15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/CBDD.12207","volume":"83","author":"H Bhatt","year":"2014","unstructured":"Bhatt H, Patel P, Pannecouque C (2014) Discovery of HIV-1 integrase inhibitors: pharmacophore mapping, virtual screening, molecular docking, synthesis, and biological evaluation. Chem Biol Drug Des 83:154\u2013166. https:\/\/doi.org\/10.1111\/CBDD.12207","journal-title":"Chem Biol Drug Des"},{"key":"3461_CR16","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1517\/14656566.2015.1044436","volume":"16","author":"JL Blanco","year":"2015","unstructured":"Blanco JL, Whitlock G, Milinkovic A, Moyle G (2015) HIV integrase inhibitors: a new era in the treatment of HIV. Exp Opin Pharmacother 16:1313\u20131324. https:\/\/doi.org\/10.1517\/14656566.2015.1044436","journal-title":"Exp Opin Pharmacother"},{"key":"3461_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1159\/000445852","volume":"43","author":"A Blut","year":"2016","unstructured":"Blut A, Blood S (2016) Assessment of PT by human immunodeficiency virus (HIV). Transfus Med Hemother 43:203. https:\/\/doi.org\/10.1159\/000445852","journal-title":"Transfus Med Hemother"},{"key":"3461_CR18","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/PHAR.2246","volume":"39","author":"KM Brooks","year":"2019","unstructured":"Brooks KM, Sherman EM, Egelund EF et al (2019) Integrase inhibitors: after 10 years of experience, is the best yet to come? Pharmacother J Hum Pharmacol Drug Ther 39:576\u2013598. https:\/\/doi.org\/10.1002\/PHAR.2246","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"3461_CR19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/S13318-018-0526-2\/TABLES\/4","volume":"44","author":"D Cattaneo","year":"2019","unstructured":"Cattaneo D, Gervasoni C (2019) Pharmacokinetics and Pharmacodynamics of cabotegravir, a long-acting HIV integrase strand transfer inhibitor. Eur J Drug Metab Pharmacokinet 44:319\u2013327. https:\/\/doi.org\/10.1007\/S13318-018-0526-2\/TABLES\/4","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"3461_CR20","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3109\/13880209.2015.1103272","volume":"54","author":"P Chaniad","year":"2016","unstructured":"Chaniad P, Wattanapiromsakul C, Pianwanit S, Tewtrakul S (2016) Anti-HIV-1 integrase compounds from Dioscorea bulbifera and molecular docking study. Pharm Biol 54:1077\u20131085. https:\/\/doi.org\/10.3109\/13880209.2015.1103272","journal-title":"Pharm Biol"},{"key":"3461_CR21","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2573965","author":"P Chaniad","year":"2019","unstructured":"Chaniad P, Sudsai T, Septama AW et al (2019) Evaluation of Anti-HIV-1 integrase and anti-inflammatory activities of compounds from betula alnoides buch-ham. Adv Pharmacol Sci. https:\/\/doi.org\/10.1155\/2019\/2573965","journal-title":"Adv Pharmacol Sci"},{"key":"3461_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/S12539-014-0235-8","volume":"7","author":"Q Chen","year":"2014","unstructured":"Chen Q, Cheng X, Wei D, Xu Q (2014) Molecular dynamics simulation studies of the wild type and E92Q\/N155H mutant of Elvitegravir-resistance HIV-1 integrase. Interdiscip Sci Comput Life Sci 7:36\u201342. https:\/\/doi.org\/10.1007\/S12539-014-0235-8","journal-title":"Interdiscip Sci Comput Life Sci"},{"key":"3461_CR23","doi-asserted-by":"publisher","DOI":"10.1101\/781120","author":"R Chitongo","year":"2019","unstructured":"Chitongo R, Obasa AE, Mikasi SG et al (2019) Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C integrase-dolutegravir binding. BioRxiv. https:\/\/doi.org\/10.1101\/781120","journal-title":"BioRxiv"},{"key":"3461_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0223464","author":"R Chitongo","year":"2020","unstructured":"Chitongo R, Obasa AE, Mikasi SG et al (2020) Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding. PLoS ONE. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0223464","journal-title":"PLoS ONE"},{"key":"3461_CR25","doi-asserted-by":"publisher","DOI":"10.4155\/FSOA-2018-0060","author":"E Choi","year":"2018","unstructured":"Choi E, Mallareddy JR, Lu D, Kolluru S (2018) Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase. Futur Sci. https:\/\/doi.org\/10.4155\/FSOA-2018-0060","journal-title":"Futur Sci"},{"key":"3461_CR26","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1126\/SCIENCE.AAY4919\/SUPPL_FILE\/PAPV2.PDF","volume":"367","author":"NJ Cook","year":"2020","unstructured":"Cook NJ, Li W, Berta D et al (2020) Structural basis of second-generation HIV integrase inhibitor action and viral resistance. Science 367:806\u2013810. https:\/\/doi.org\/10.1126\/SCIENCE.AAY4919\/SUPPL_FILE\/PAPV2.PDF","journal-title":"Science"},{"key":"3461_CR27","doi-asserted-by":"publisher","first-page":"722","DOI":"10.3390\/LIFE11070722","volume":"11","author":"L Crisan","year":"2021","unstructured":"Crisan L, Bora A (2021) Small molecules of natural origin as potential anti-HIV agents: a computational approach. Life 11:722. https:\/\/doi.org\/10.3390\/LIFE11070722","journal-title":"Life"},{"key":"3461_CR28","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1146\/ANNUREV-MED-092112-152941","volume":"66","author":"MS Dahabieh","year":"2015","unstructured":"Dahabieh MS, Battivelli E, Verdin E (2015) Understanding HIV latency: the road to an HIV cure. Annu Rev Med 66:407. https:\/\/doi.org\/10.1146\/ANNUREV-MED-092112-152941","journal-title":"Annu Rev Med"},{"key":"3461_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0077448","volume":"8","author":"F DeAnda","year":"2013","unstructured":"DeAnda F, Hightower KE, Nolte RT et al (2013) Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics. PLoS ONE 8:e77448. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0077448","journal-title":"PLoS ONE"},{"key":"3461_CR30","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/S40265-018-1010-7","volume":"78","author":"ED Deeks","year":"2018","unstructured":"Deeks ED (2018) Bictegravir\/emtricitabine\/tenofovir alafenamide: a review in HIV-1 infection. Drugs 78:1817. https:\/\/doi.org\/10.1007\/S40265-018-1010-7","journal-title":"Drugs"},{"key":"3461_CR31","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1021\/JM400674A\/ASSET\/IMAGES\/LARGE\/JM-2013-00674A_0014.JPEG","volume":"57","author":"R Di Santo","year":"2014","unstructured":"Di Santo R (2014) Inhibiting the HIV integration process: past, present, and the future. J Med Chem 57:539\u2013566. https:\/\/doi.org\/10.1021\/JM400674A\/ASSET\/IMAGES\/LARGE\/JM-2013-00674A_0014.JPEG","journal-title":"J Med Chem"},{"key":"3461_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/V9050105","volume":"9","author":"J Ding","year":"2017","unstructured":"Ding J, Zhao J, Yang Z et al (2017) Microbial natural product alternariol 5-O-methyl ether inhibits HIV-1 integration by blocking nuclear import of the pre-integration complex. Viruses 9:105. https:\/\/doi.org\/10.3390\/V9050105","journal-title":"Viruses"},{"key":"3461_CR33","doi-asserted-by":"publisher","first-page":"2000012","DOI":"10.1002\/MINF.202000012","volume":"40","author":"B Dogan","year":"2021","unstructured":"Dogan B, Durdagi S (2021) Drug re-positioning studies for novel HIV-1 inhibitors using binary QSAR models and multi-target-driven in silico studies. Mol Inform 40:2000012. https:\/\/doi.org\/10.1002\/MINF.202000012","journal-title":"Mol Inform"},{"key":"3461_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PCBI.1006155","volume":"14","author":"S Duwal","year":"2018","unstructured":"Duwal S, Dickinson L, Khoo S, von Kleist M (2018) Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: an example with different dolutegravir prophylaxis schemes. PLOS Comput Biol 14:e1006155. https:\/\/doi.org\/10.1371\/JOURNAL.PCBI.1006155","journal-title":"PLOS Comput Biol"},{"key":"3461_CR35","doi-asserted-by":"publisher","DOI":"10.7717\/PEERJ-PCHEM.6","volume":"1","author":"L El Khoury","year":"2019","unstructured":"El Khoury L, El HK, Piquemal J-P et al (2019) Spectrometric and computational studies of the binding of HIV-1 integrase inhibitors to viral DNA extremities. PeerJ Phys Chem 1:e6. https:\/\/doi.org\/10.7717\/PEERJ-PCHEM.6","journal-title":"PeerJ Phys Chem"},{"key":"3461_CR36","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/0739110220191700166","volume":"38","author":"S Ercan","year":"2019","unstructured":"Ercan S, \u015eenyi\u011fit B, \u015eenses Y (2019) Dual inhibitor design for HIV-1 reverse transcriptase and integrase enzymes: a molecular docking study. J Biomol Struct Dyn 38:573\u2013580. https:\/\/doi.org\/10.1080\/0739110220191700166","journal-title":"J Biomol Struct Dyn"},{"key":"3461_CR37","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1134\/S0022093021020101","volume":"57","author":"S Esmaeili","year":"2021","unstructured":"Esmaeili S, Mosaddeghi H, Ravari F (2021) Molecular docking studies of HIV-1 protease-, integrase- and reverse-transcriptase with delta-9-tetrahydrocannabinol and curcumin as two herbal ligands. J Evol Biochem Physiol 57:281\u2013288. https:\/\/doi.org\/10.1134\/S0022093021020101","journal-title":"J Evol Biochem Physiol"},{"key":"3461_CR38","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2147\/HIV.S300055","volume":"13","author":"N Evans","year":"2021","unstructured":"Evans N, Martinez E, Petrosillo N et al (2021) SARS-CoV-2 and human immunodeficiency virus: pathogen pincer attack. HIV\/AIDS Res Palliat Care 13:361\u2013375. https:\/\/doi.org\/10.2147\/HIV.S300055","journal-title":"HIV\/AIDS Res Palliat Care"},{"key":"3461_CR39","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1128\/AAC.02719-13","volume":"58","author":"C Fenwick","year":"2014","unstructured":"Fenwick C, Amad M, Bailey MD et al (2014) Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor. Antimicrob Agents Chemother 58:3233. https:\/\/doi.org\/10.1128\/AAC.02719-13","journal-title":"Antimicrob Agents Chemother"},{"key":"3461_CR40","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2147\/HIV.S184642","volume":"11","author":"C Fernandez","year":"2019","unstructured":"Fernandez C, van Halsema CL (2019) Evaluating cabotegravir\/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential. HIV AIDS (auckl) 11:179. https:\/\/doi.org\/10.2147\/HIV.S184642","journal-title":"HIV AIDS (auckl)"},{"key":"3461_CR41","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1093\/CID\/CIY228","volume":"67","author":"JA Fulcher","year":"2018","unstructured":"Fulcher JA, Du Y, Zhang TH et al (2018) Emergence of integrase resistance mutations during initial therapy containing dolutegravir. Clin Infect Dis 67:791\u2013794. https:\/\/doi.org\/10.1093\/CID\/CIY228","journal-title":"Clin Infect Dis"},{"key":"3461_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/J.BBREP.2022.101254","volume":"30","author":"F Ghasabi","year":"2022","unstructured":"Ghasabi F, Hashempour A, Khodadad N et al (2022) First report of computational protein\u2013ligand docking to evaluate susceptibility to HIV integrase inhibitors in HIV-infected Iranian patients. Biochem Biophys Rep 30:101254. https:\/\/doi.org\/10.1016\/J.BBREP.2022.101254","journal-title":"Biochem Biophys Rep"},{"key":"3461_CR43","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3390\/V12050564","volume":"12","author":"Y Gong","year":"2020","unstructured":"Gong Y, Zhi K, Nagesh PKB et al (2020) An elvitegravir nanoformulation crosses the blood\u2013brain barrier and suppresses HIV-1 replication in microglia. Viruses 12:564. https:\/\/doi.org\/10.3390\/V12050564","journal-title":"Viruses"},{"key":"3461_CR44","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2174\/157340913804998793","volume":"9","author":"P Gupta","year":"2013","unstructured":"Gupta P, Sharma A, Garg P, Roy N (2013) QSAR study of curcumine derivatives as HIV-1 integrase inhibitors. Curr Comput Aided Drug Des 9:141\u2013150. https:\/\/doi.org\/10.2174\/157340913804998793","journal-title":"Curr Comput Aided Drug Des"},{"key":"3461_CR45","doi-asserted-by":"publisher","first-page":"27594","DOI":"10.1039\/C6RA00713A","volume":"6","author":"D Han","year":"2016","unstructured":"Han D, Su M, Tan J et al (2016) Structure\u2013activity relationship and binding mode studies for a series of diketo-acids as HIV integrase inhibitors by 3D-QSAR, molecular docking and molecular dynamics simulations. RSC Adv 6:27594\u201327606. https:\/\/doi.org\/10.1039\/C6RA00713A","journal-title":"RSC Adv"},{"key":"3461_CR46","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/JAC\/DKU387","volume":"70","author":"I Hardy","year":"2015","unstructured":"Hardy I, Brenner B, Quashie P et al (2015) Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. J Antimicrob Chemother 70:405\u2013411. https:\/\/doi.org\/10.1093\/JAC\/DKU387","journal-title":"J Antimicrob Chemother"},{"key":"3461_CR47","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1021\/NP0340504\/SUPPL_FILE\/NP0340504SI20040209_030413.PDF","volume":"67","author":"KB Herath","year":"2004","unstructured":"Herath KB, Jayasuriya H, Bills GF et al (2004) Isolation, structure, absolute stereochemistry, and HIV-1 integrase inhibitory activity of integrasone, a novel fungal polyketide. J Nat Prod 67:872\u2013874. https:\/\/doi.org\/10.1021\/NP0340504\/SUPPL_FILE\/NP0340504SI20040209_030413.PDF","journal-title":"J Nat Prod"},{"key":"3461_CR48","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2147\/HIV.S145529","volume":"10","author":"L Hill","year":"2018","unstructured":"Hill L, Smith SR, Karris MY (2018) Profile of bictegravir\/emtricitabine\/tenofovir alafenamide fixed dose combination and its potential in the treatment of HIV-1 infection: evidence to date. HIV AIDS (auckl) 10:203. https:\/\/doi.org\/10.2147\/HIV.S145529","journal-title":"HIV AIDS (auckl)"},{"key":"3461_CR49","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/S40262-021-01005-1\/FIGURES\/4","volume":"60","author":"D Hodge","year":"2021","unstructured":"Hodge D, Back DJ, Gibbons S et al (2021) Pharmacokinetics and drug\u2013drug interactions of long-acting intramuscular cabotegravir and rilpivirine. Clin Pharmacokinet 60:835\u2013853. https:\/\/doi.org\/10.1007\/S40262-021-01005-1\/FIGURES\/4","journal-title":"Clin Pharmacokinet"},{"key":"3461_CR50","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1093\/CID\/CIY653","volume":"68","author":"CJ Hoesley","year":"2019","unstructured":"Hoesley CJ, Chen BA, Anderson PL et al (2019) Phase 1 safety and pharmacokinetics study of MK-2048\/Vicriviroc (MK-4176)\/MK-2048A intravaginal rings. Clin Infect Dis 68:1136\u20131143. https:\/\/doi.org\/10.1093\/CID\/CIY653","journal-title":"Clin Infect Dis"},{"key":"3461_CR51","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.3389\/FPHAR.2019.01225\/BIBTEX","volume":"10","author":"Y Huang","year":"2019","unstructured":"Huang Y, Huang X, Chen H et al (2019) Efficacy and safety of raltegravir-based dual therapy in AIDS patients: a meta-analysis of randomized controlled trials. Front Pharmacol 10:1225. https:\/\/doi.org\/10.3389\/FPHAR.2019.01225\/BIBTEX","journal-title":"Front Pharmacol"},{"key":"3461_CR52","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1016\/J.JIPH.2020.10.015","volume":"13","author":"P Indu","year":"2020","unstructured":"Indu P, Rameshkumar MR, Arunagirinathan N et al (2020) Raltegravir, indinavir, tipranavir, dolutegravir, and etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach. J Infect Public Health 13:1856\u20131861. https:\/\/doi.org\/10.1016\/J.JIPH.2020.10.015","journal-title":"J Infect Public Health"},{"key":"3461_CR53","doi-asserted-by":"publisher","first-page":"936","DOI":"10.3390\/V12090936","volume":"12","author":"D Isaacs","year":"2020","unstructured":"Isaacs D, Mikasi SG, Obasa AE et al (2020) Structural comparison of diverse HIV-1 subtypes using molecular modelling and docking analyses of integrase inhibitors. Viruses 12:936. https:\/\/doi.org\/10.3390\/V12090936","journal-title":"Viruses"},{"key":"3461_CR54","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1039\/C5MB00767D","volume":"12","author":"MA Islam","year":"2016","unstructured":"Islam MA, Pillay TS (2016) Structural requirements for potential HIV-integrase inhibitors identified using pharmacophore-based virtual screening and molecular dynamics studies. Mol Biosyst 12:982\u2013993. https:\/\/doi.org\/10.1039\/C5MB00767D","journal-title":"Mol Biosyst"},{"key":"3461_CR55","doi-asserted-by":"publisher","DOI":"10.1177\/2325958218821653","author":"SL Kang-Birken","year":"2019","unstructured":"Kang-Birken SL, El-sayed D, Prichard J (2019) HIV viral rebound due to a possible drug\u2013drug interaction between elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide and calcium-containing products: report of 2 cases. J Int Assoc Provid AIDS Care. https:\/\/doi.org\/10.1177\/2325958218821653","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"3461_CR56","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.3390\/MOLECULES25092070","volume":"25","author":"R Kaur","year":"2020","unstructured":"Kaur R, Sharma P, Gupta GK et al (2020) Structure-activity-relationship and mechanistic insights for anti-HIV natural products. Mol 25:2070. https:\/\/doi.org\/10.3390\/MOLECULES25092070","journal-title":"Mol"},{"issue":"11","key":"3461_CR57","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/S40506-019-00203-7","volume":"114","author":"A Kolakowska","year":"2019","unstructured":"Kolakowska A, Maresca AF, Collins IJ (2019) Update on adverse effects of HIV integrase inhibitors. Curr Treat Options Infect Dis 114(11):372\u2013387. https:\/\/doi.org\/10.1007\/S40506-019-00203-7","journal-title":"Curr Treat Options Infect Dis"},{"key":"3461_CR58","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.3389\/FMICB.2019.02828\/BIBTEX","volume":"10","author":"Z Kruize","year":"2019","unstructured":"Kruize Z, Kootstra NA (2019) The role of macrophages in HIV-1 persistence and pathogenesis. Front Microbiol 10:2828. https:\/\/doi.org\/10.3389\/FMICB.2019.02828\/BIBTEX","journal-title":"Front Microbiol"},{"key":"3461_CR59","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/B978-0-323-04579-7.00145-3","volume":"2","author":"CJ Kubin","year":"2010","unstructured":"Kubin CJ, Hammer SM (2010) Antiretroviral agents. Infect Dis Third Ed 2:1434\u20131453. https:\/\/doi.org\/10.1016\/B978-0-323-04579-7.00145-3","journal-title":"Infect Dis Third Ed"},{"key":"3461_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/FMICB.2015.01444","author":"KRV Kurapati","year":"2015","unstructured":"Kurapati KRV, Atluri VS, Samikkannu T et al (2015) Natural products as anti-HIV agents and role in HIV-associated neurocognitive disorders (HAND): a brief overview. Front Microbiol. https:\/\/doi.org\/10.3389\/FMICB.2015.01444","journal-title":"Front Microbiol"},{"key":"3461_CR61","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1128\/MMBR.00065-15\/SUPPL_FILE\/ZMR003162428SO1.PDF","volume":"80","author":"G Li","year":"2016","unstructured":"Li G, De Clercq E (2016) HIV genome-wide protein associations: a review of 30 years of research. Microbiol Mol Biol Rev 80:679\u2013731. https:\/\/doi.org\/10.1128\/MMBR.00065-15\/SUPPL_FILE\/ZMR003162428SO1.PDF","journal-title":"Microbiol Mol Biol Rev"},{"key":"3461_CR62","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.3389\/FMICB.2018.02325\/BIBTEX","volume":"9","author":"R Linnakoski","year":"2018","unstructured":"Linnakoski R, Reshamwala D, Veteli P et al (2018) Antiviral agents from fungi: diversity, mechanisms and potential applications. Front Microbiol 9:2325. https:\/\/doi.org\/10.3389\/FMICB.2018.02325\/BIBTEX","journal-title":"Front Microbiol"},{"key":"3461_CR63","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/J.CRBIOT.2021.04.003","volume":"3","author":"J Liu","year":"2021","unstructured":"Liu J, Obaidi I, Nagar S et al (2021) The antiviral potential of algal-derived macromolecules. Curr Res Biotechnol 3:120\u2013134. https:\/\/doi.org\/10.1016\/J.CRBIOT.2021.04.003","journal-title":"Curr Res Biotechnol"},{"key":"3461_CR64","doi-asserted-by":"publisher","first-page":"333","DOI":"10.22037\/IJPR.2021.115446.15370","volume":"20","author":"M Mahboubi-Rabbani","year":"2021","unstructured":"Mahboubi-Rabbani M, Abbasi M, Hajimahdi Z, Zarghi A (2021) HIV-1 reverse transcriptase\/integrase dual inhibitors: a review of recent advances and structure-activity relationship studies. Iran J Pharm Res IJPR 20:333. https:\/\/doi.org\/10.22037\/IJPR.2021.115446.15370","journal-title":"Iran J Pharm Res IJPR"},{"key":"3461_CR65","doi-asserted-by":"publisher","first-page":"937","DOI":"10.3390\/V12090937","volume":"12","author":"P Makoti","year":"2020","unstructured":"Makoti P, Fielding BC (2020) HIV and human coronavirus coinfections: a historical perspective. Viruses 12:937. https:\/\/doi.org\/10.3390\/V12090937","journal-title":"Viruses"},{"key":"3461_CR66","doi-asserted-by":"publisher","DOI":"10.1128\/MBIO.00922-17\/ASSET\/AAECBCCA-7EAF-4566-AC85-49E1B03887ED\/ASSETS\/GRAPHIC\/MBO0051735020005.JPEG","author":"I Malet","year":"2017","unstructured":"Malet I, Subra F, Charpentier C et al (2017) Mutations located outside the integrase gene can confer resistance to HIV-1 integrase strand transfer inhibitors. Mbio. https:\/\/doi.org\/10.1128\/MBIO.00922-17\/ASSET\/AAECBCCA-7EAF-4566-AC85-49E1B03887ED\/ASSETS\/GRAPHIC\/MBO0051735020005.JPEG","journal-title":"Mbio"},{"key":"3461_CR67","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1093\/JAC\/DKX529","volume":"73","author":"I Malet","year":"2018","unstructured":"Malet I, Ambrosio FA, Subra F et al (2018) Pathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance. J Antimicrob Chemother 73:1158\u20131166. https:\/\/doi.org\/10.1093\/JAC\/DKX529","journal-title":"J Antimicrob Chemother"},{"key":"3461_CR68","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/B978-0-12-817907-9.00009-X","volume":"66","author":"A Mandal","year":"2020","unstructured":"Mandal A, Biswas D, Hazra B (2020) Natural products from plants with prospective anti-HIV activity and relevant mechanisms of action. Stud Nat Prod Chem 66:225\u2013271. https:\/\/doi.org\/10.1016\/B978-0-12-817907-9.00009-X","journal-title":"Stud Nat Prod Chem"},{"key":"3461_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-409547-2.11305-8","author":"YC Martin","year":"2014","unstructured":"Martin YC (2014) Applications of pharmacophore mapping. Ref Modul Chem Mol Sci Chem Eng. https:\/\/doi.org\/10.1016\/B978-0-12-409547-2.11305-8","journal-title":"Ref Modul Chem Mol Sci Chem Eng"},{"key":"3461_CR70","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/J.ANTIVIRAL.2014.03.006","volume":"106","author":"M Masso","year":"2014","unstructured":"Masso M, Chuang G, Hao K et al (2014) Structure-based predictors of resistance to the HIV-1 integrase inhibitor Elvitegravir. Antiviral Res 106:5\u201312. https:\/\/doi.org\/10.1016\/J.ANTIVIRAL.2014.03.006","journal-title":"Antiviral Res"},{"key":"3461_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJANTIMICAG.2021.106343","volume":"57","author":"N Mbhele","year":"2021","unstructured":"Mbhele N, Chimukangara B, Gordon M (2021) HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance. Int J Antimicrob Agents 57:106343. https:\/\/doi.org\/10.1016\/J.IJANTIMICAG.2021.106343","journal-title":"Int J Antimicrob Agents"},{"key":"3461_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12879-021-06059-X\/FIGURES\/4","volume":"21","author":"SG Mikasi","year":"2021","unstructured":"Mikasi SG, Isaacs D, Chitongo R et al (2021) Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations. BMC Infect Dis 21:1\u201312. https:\/\/doi.org\/10.1186\/S12879-021-06059-X\/FIGURES\/4","journal-title":"BMC Infect Dis"},{"key":"3461_CR73","unstructured":"NACO (2013) National guidelines on second-line and alternative first-line ART for adults and adolescents"},{"key":"3461_CR74","unstructured":"NACO (2019) HIV Facts & Figures | National AIDS Control Organization | MoHFW | GoI. In: NACO. http:\/\/naco.gov.in\/hiv-facts-figures. Accessed 4 Mar 2022"},{"key":"3461_CR75","unstructured":"National Institutes of Health (2022) What\u2019s New in the Guidelines? | NIH. In: Clin. INFO.HIV.GOV, NIH. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv\/whats-new-guidelines. Accessed 25 Mar 2022"},{"key":"3461_CR76","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/J.JPHOTOBIOL.2018.10.025","volume":"189","author":"O Nobela","year":"2018","unstructured":"Nobela O, Renslow RS, Thomas DG et al (2018) Efficient discrimination of natural stereoisomers of chicoric acid, an HIV-1 integrase inhibitor. J Photochem Photobiol B Biol 189:258\u2013266. https:\/\/doi.org\/10.1016\/J.JPHOTOBIOL.2018.10.025","journal-title":"J Photochem Photobiol B Biol"},{"key":"3461_CR77","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.2147\/DDDT.S133170","volume":"11","author":"F Notario-P\u00e9rez","year":"2017","unstructured":"Notario-P\u00e9rez F, Ruiz-Caro R, Veiga-Ochoa MD (2017) Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes. Drug Des Devel Ther 11:1767\u20131787. https:\/\/doi.org\/10.2147\/DDDT.S133170","journal-title":"Drug Des Devel Ther"},{"key":"3461_CR78","first-page":"167","volume":"2","author":"A Nusrath Unissa","year":"2017","unstructured":"Nusrath Unissa A, Swathi S, Ramya Lakshmi A, Elizabeth Hanna L (2017) Insights into Integrase resistance to dolutegravir, elvitegravir and raltegravir-strand transfer inhibitors of HIV-1: a computational approach. Orig Res Artic Saudi J Pathol Microbiol 2:167\u2013175","journal-title":"Orig Res Artic Saudi J Pathol Microbiol"},{"key":"3461_CR79","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/S12977-018-0440-3","volume":"15","author":"M Oliveira","year":"2018","unstructured":"Oliveira M, Ibanescu RI, Anstett K et al (2018) Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. Retrovirology 15:56. https:\/\/doi.org\/10.1186\/S12977-018-0440-3","journal-title":"Retrovirology"},{"key":"3461_CR80","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.3109\/13880209.2015.1014568","volume":"53","author":"P Panthong","year":"2015","unstructured":"Panthong P, Bunluepuech K, Boonnak N et al (2015) Anti-HIV-1 integrase activity and molecular docking of compounds from Albizia procera bark. Pharm Biol 53:1861\u20131866. https:\/\/doi.org\/10.3109\/13880209.2015.1014568","journal-title":"Pharm Biol"},{"key":"3461_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12985-020-01476-X\/FIGURES\/4","volume":"18","author":"KH Park","year":"2021","unstructured":"Park KH, Kim M, Bae SE et al (2021) Study on suitable analysis method for HIV-1 non-catalytic integrase inhibitor. Virol J 18:1\u20139. https:\/\/doi.org\/10.1186\/S12985-020-01476-X\/FIGURES\/4","journal-title":"Virol J"},{"key":"3461_CR82","doi-asserted-by":"publisher","first-page":"e620","DOI":"10.1016\/S2214-109X(21)00025-5\/ATTACHMENT\/092D2DBF-6FBA-4226-8B75-0924D14C906A\/MMC1.PDF","volume":"9","author":"AN Phillips","year":"2021","unstructured":"Phillips AN, Bansi-Matharu L, Cambiano V et al (2021) The potential role of long-acting injectable cabotegravir\u2013rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis. Lancet Glob Heal 9:e620\u2013e627. https:\/\/doi.org\/10.1016\/S2214-109X(21)00025-5\/ATTACHMENT\/092D2DBF-6FBA-4226-8B75-0924D14C906A\/MMC1.PDF","journal-title":"Lancet Glob Heal"},{"key":"3461_CR83","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/S40262-016-0424-1","volume":"56","author":"AT Podany","year":"2017","unstructured":"Podany AT, Scarsi KK, Fletcher CV (2017) Comparative clinical pharmacokinetics and pharmacodynamics of HIV-1 integrase strand transfer inhibitors. Clin Pharmacokinet 56:25. https:\/\/doi.org\/10.1007\/S40262-016-0424-1","journal-title":"Clin Pharmacokinet"},{"key":"3461_CR84","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/S00203-017-1448-0\/FIGURES\/5","volume":"200","author":"C Putim","year":"2018","unstructured":"Putim C, Phaonakrop N, Jaresitthikunchai J et al (2018) Secretome profile analysis of multidrug-resistant, monodrug-resistant and drug-susceptible Mycobacterium tuberculosis. Arch Microbiol 200:299\u2013309. https:\/\/doi.org\/10.1007\/S00203-017-1448-0\/FIGURES\/5","journal-title":"Arch Microbiol"},{"key":"3461_CR85","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1128\/JVI.06591-11\/ASSET\/C94B8E9C-DC59-486E-AEC2-9C3D1E3BD09A\/ASSETS\/GRAPHIC\/ZJV9990957020005.JPEG","volume":"86","author":"PK Quashie","year":"2012","unstructured":"Quashie PK, Mespl\u00e8de T, Han Y-S et al (2012) Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 86:2696\u20132705. https:\/\/doi.org\/10.1128\/JVI.06591-11\/ASSET\/C94B8E9C-DC59-486E-AEC2-9C3D1E3BD09A\/ASSETS\/GRAPHIC\/ZJV9990957020005.JPEG","journal-title":"J Virol"},{"issue":"203","key":"3461_CR86","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/S00203-021-02256-Z","volume":"2035","author":"A Raimi","year":"2021","unstructured":"Raimi A (2021) Adeleke R (2021) Bioprospecting of endophytic microorganisms for bioactive compounds of therapeutic importance. Arch Microbiol 2035(203):1917\u20131942. https:\/\/doi.org\/10.1007\/S00203-021-02256-Z","journal-title":"Arch Microbiol"},{"key":"3461_CR87","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1007\/S00203-021-02183-Z\/TABLES\/1","volume":"203","author":"CTD Raj","year":"2021","unstructured":"Raj CTD, Kandaswamy DK, Danduga RCSR et al (2021) COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics\u2014a review. Arch Microbiol 203:2043\u20132057. https:\/\/doi.org\/10.1007\/S00203-021-02183-Z\/TABLES\/1","journal-title":"Arch Microbiol"},{"key":"3461_CR88","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/S00210-020-01901-6","volume":"393","author":"M Rameshrad","year":"2020","unstructured":"Rameshrad M, Ghafoori M, Mohammadpour AH et al (2020) A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19). Naunyn Schmiedebergs Arch Pharmacol 393:1137. https:\/\/doi.org\/10.1007\/S00210-020-01901-6","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"3461_CR89","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1080\/1062936X.2013.772919","volume":"24","author":"KK Reddy","year":"2013","unstructured":"Reddy KK, Singh SK, Tripathi SK, Selvaraj C (2013) Identification of potential HIV-1 integrase strand transfer inhibitors: In silico virtual screening and QM\/MM docking studies. SAR QSAR Environ Res 24:581\u2013595. https:\/\/doi.org\/10.1080\/1062936X.2013.772919","journal-title":"SAR QSAR Environ Res"},{"key":"3461_CR90","doi-asserted-by":"publisher","first-page":"102331","DOI":"10.1016\/J.ALGAL.2021.102331","volume":"57","author":"D Reynolds","year":"2021","unstructured":"Reynolds D, Huesemann M, Edmundson S et al (2021) Viral inhibitors derived from macroalgae, microalgae, and cyanobacteria: a review of antiviral potential throughout pathogenesis. Algal Res 57:102331. https:\/\/doi.org\/10.1016\/J.ALGAL.2021.102331","journal-title":"Algal Res"},{"key":"3461_CR91","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1093\/JAC\/DKZ256","volume":"74","author":"SY Rhee","year":"2019","unstructured":"Rhee SY, Grant PM, Tzou PL et al (2019) A systematic review of the genetic mechanisms of dolutegravir resistance. J Antimicrob Chemother 74:3135\u20133149. https:\/\/doi.org\/10.1093\/JAC\/DKZ256","journal-title":"J Antimicrob Chemother"},{"key":"3461_CR92","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3390\/BIOM10071007","volume":"10","author":"G Riccio","year":"2020","unstructured":"Riccio G, Ruocco N, Mutalipassi M et al (2020) Ten-year research update review: antiviral activities from marine organisms. Biomol 10:1007. https:\/\/doi.org\/10.3390\/BIOM10071007","journal-title":"Biomol"},{"key":"3461_CR93","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/JA.2005.34","volume":"58","author":"S Rochfort","year":"2005","unstructured":"Rochfort S, Ford J, Ovenden S et al (2005) A novel aspochalasin with HIV-1 integrase inhibitory activity from Aspergillus flavipes. J Antibiot (tokyo) 58:279\u2013283. https:\/\/doi.org\/10.1038\/JA.2005.34","journal-title":"J Antibiot (tokyo)"},{"key":"3461_CR94","volume-title":"Hiv integrase mechanisms of resistance to Raltegravir, Elvitegravir","author":"K Ross","year":"2015","unstructured":"Ross K (2015) Hiv integrase mechanisms of resistance to Raltegravir, Elvitegravir. Graduate School of Wayne State University, Dolutegravir"},{"key":"3461_CR95","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3390\/LIFE11020100","volume":"11","author":"E Rossi","year":"2021","unstructured":"Rossi E, Meuser ME, Cunanan CJ, Cocklin S (2021) Structure, function, and interactions of the HIV-1 capsid protein. Life 11:100. https:\/\/doi.org\/10.3390\/LIFE11020100","journal-title":"Life"},{"key":"3461_CR96","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ymben.2018.07.013","volume":"49","author":"J Roulet","year":"2018","unstructured":"Roulet J, Taton A, Golden JW et al (2018) Development of a cyanobacterial heterologous polyketide production platform. Metab Eng 49:94\u2013104. https:\/\/doi.org\/10.1016\/j.ymben.2018.07.013","journal-title":"Metab Eng"},{"key":"3461_CR97","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/2040206617705500","volume":"25","author":"BG Roy","year":"2017","unstructured":"Roy BG (2017) Potential of small-molecule fungal metabolites in antiviral chemotherapy. Antivir Chem Chemother 25:20\u201352. https:\/\/doi.org\/10.1177\/2040206617705500","journal-title":"Antivir Chem Chemother"},{"key":"3461_CR98","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.3390\/IJMS19051459","volume":"19","author":"B Salehi","year":"2018","unstructured":"Salehi B, Anil Kumar NV, \u015eener B et al (2018) Medicinal plants used in the treatment of human immunodeficiency virus. Int J Mol Sci 19:1459. https:\/\/doi.org\/10.3390\/IJMS19051459","journal-title":"Int J Mol Sci"},{"key":"3461_CR99","doi-asserted-by":"publisher","first-page":"4644","DOI":"10.1080\/07391102.2018.1557559","volume":"37","author":"AS Samorlu","year":"2019","unstructured":"Samorlu AS, Yelek\u00e7i K, Ibrahim Uba A (2019) The design of potent HIV-1 integrase inhibitors by a combined approach of structure-based virtual screening and molecular dynamics. SIMULATION 37:4644\u20134650. https:\/\/doi.org\/10.1080\/07391102.2018.1557559","journal-title":"SIMULATION"},{"key":"3461_CR100","unstructured":"Schr\u00f6dinger L, DeLano W (2020) PyMOL. http:\/\/www.pymol.org\/pymol. Accessed 18 Feb 2023"},{"key":"3461_CR101","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/J.JGAR.2019.07.015","volume":"20","author":"R Scutari","year":"2020","unstructured":"Scutari R, Alteri C, Vicenti I et al (2020) Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors. J Glob Antimicrob Resist 20:163\u2013169. https:\/\/doi.org\/10.1016\/J.JGAR.2019.07.015","journal-title":"J Glob Antimicrob Resist"},{"key":"3461_CR102","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/V13040594","volume":"13","author":"KK Seatla","year":"2021","unstructured":"Seatla KK, Maruapula D, Choga WT et al (2021) HIV-1 subtype C drug resistance mutations in heavily treated patients failing integrase strand transfer inhibitor-based regimens in Botswana. Viruses 13:594. https:\/\/doi.org\/10.3390\/V13040594","journal-title":"Viruses"},{"issue":"58","key":"3461_CR103","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/ja.2005.8","volume":"581","author":"K Shiomi","year":"2005","unstructured":"Shiomi K, Matsui R, Isozaki M et al (2005) Fungal phenalenones inhibit HIV-1 integrase. J Antibiot 581(58):65\u201368. https:\/\/doi.org\/10.1038\/ja.2005.8","journal-title":"J Antibiot"},{"key":"3461_CR104","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/S10295-003-0101-X","volume":"30","author":"SB Singh","year":"2003","unstructured":"Singh SB, Jayasuriya H, Dewey R et al (2003) Isolation, structure, and HIV-1-integrase inhibitory activity of structurally diverse fungal metabolites. J Ind Microbiol Biotechnol 30:721\u2013731. https:\/\/doi.org\/10.1007\/S10295-003-0101-X","journal-title":"J Ind Microbiol Biotechnol"},{"issue":"9","key":"3461_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-41403-x","volume":"91","author":"X Siwe-Noundou","year":"2019","unstructured":"Siwe-Noundou X, Musyoka TM, Moses V et al (2019) Anti-HIV-1 integrase potency of methylgallate from Alchornea cordifolia using in vitro and in silico approaches. Sci Rep 91(9):1\u20139. https:\/\/doi.org\/10.1038\/s41598-019-41403-x","journal-title":"Sci Rep"},{"key":"3461_CR106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12977-018-0420-7\/FIGURES\/11","volume":"15","author":"SJ Smith","year":"2018","unstructured":"Smith SJ, Zhao XZ, Burke TR, Hughes SH (2018) Efficacies of cabotegravir and bictegravir against drug-resistant HIV-1 integrase mutants. Retrovirology 15:1\u201318. https:\/\/doi.org\/10.1186\/S12977-018-0420-7\/FIGURES\/11","journal-title":"Retrovirology"},{"key":"3461_CR107","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00611-20\/SUPPL_FILE\/AAC.00611-20-S0001.PDF","author":"SJ Smith","year":"2020","unstructured":"Smith SJ, Zhao XZ, Passos DO et al (2020) HIV-1 integrase inhibitors that are active against drug-resistant integrase mutants. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.00611-20\/SUPPL_FILE\/AAC.00611-20-S0001.PDF","journal-title":"Antimicrob Agents Chemother"},{"key":"3461_CR108","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1021\/ACSINFECDIS.0C00819\/SUPPL_FILE\/ID0C00819_LIVESLIDES.MP4","volume":"7","author":"SJ Smith","year":"2021","unstructured":"Smith SJ, Zhao XZ, Passos DO et al (2021a) HIV-1 integrase inhibitors with modifications that affect their potencies against drug resistant integrase mutants. ACS Infect Dis 7:1469\u20131482. https:\/\/doi.org\/10.1021\/ACSINFECDIS.0C00819\/SUPPL_FILE\/ID0C00819_LIVESLIDES.MP4","journal-title":"ACS Infect Dis"},{"key":"3461_CR109","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3390\/V13020205","volume":"13","author":"SJ Smith","year":"2021","unstructured":"Smith SJ, Zhao XZ, Passos DO et al (2021b) Integrase Strand transfer inhibitors are effective anti-HIV drugs. Viruses 13:205. https:\/\/doi.org\/10.3390\/V13020205","journal-title":"Viruses"},{"key":"3461_CR110","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1002\/CPT.2221","volume":"110","author":"F Stader","year":"2021","unstructured":"Stader F, Battegay M, Marzolini C (2021) Physiologically-based pharmacokinetic modeling to support the clinical management of drug-drug interactions with Bictegravir. Clin Pharmacol Ther 110:1231\u20131239. https:\/\/doi.org\/10.1002\/CPT.2221","journal-title":"Clin Pharmacol Ther"},{"key":"3461_CR111","unstructured":"Stanford HIV-1 Drug Resistance Database (2019) INSTI resistance notes\u2014HIV drug resistance database. In: Stanford Univ. https:\/\/hivdb.stanford.edu\/dr-summary\/resistance-notes\/INSTI\/. Accessed 1 Apr 2022"},{"key":"3461_CR112","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/PTR.5307","volume":"29","author":"S Tewtrakul","year":"2015","unstructured":"Tewtrakul S, Chaniad P, Pianwanit S et al (2015) Anti-HIV-1 integrase activity and molecular docking study of compounds from Caesalpinia sappan L. Phytother Res 29:724\u2013729. https:\/\/doi.org\/10.1002\/PTR.5307","journal-title":"Phytother Res"},{"key":"3461_CR113","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.3389\/FMICB.2016.02165\/BIBTEX","volume":"7","author":"E Thierry","year":"2017","unstructured":"Thierry E, Deprez E, Delelis O (2017) Different pathways leading to integrase inhibitors resistance. Front Microbiol 7:2165. https:\/\/doi.org\/10.3389\/FMICB.2016.02165\/BIBTEX","journal-title":"Front Microbiol"},{"key":"3461_CR114","unstructured":"UNAIDS (2021) Global HIV & AIDS statistics\u2014fact sheet. In: UNAIDS. https:\/\/www.unaids.org\/en\/resources\/fact-sheet. Accessed 27 Feb 2022"},{"key":"3461_CR115","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1080\/14656566.2016.1250885","volume":"17","author":"NR Unger","year":"2016","unstructured":"Unger NR, Worley MV, Kisgen JJ et al (2016) Elvitegravir for the treatment of HIV. Expert Opin Pharmacother 17:2359\u20132370. https:\/\/doi.org\/10.1080\/14656566.2016.1250885","journal-title":"Expert Opin Pharmacother"},{"key":"3461_CR116","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/S40262-018-0684-Z\/TABLES\/4","volume":"58","author":"R van der Gali\u00ebn","year":"2019","unstructured":"van der Gali\u00ebn R, ter Heine R, Greupink R et al (2019) Pharmacokinetics of HIV-integrase inhibitors during pregnancy: mechanisms, clinical implications and knowledge gaps. Clin Pharmacokinet 58:309\u2013323. https:\/\/doi.org\/10.1007\/S40262-018-0684-Z\/TABLES\/4","journal-title":"Clin Pharmacokinet"},{"key":"3461_CR117","doi-asserted-by":"publisher","first-page":"14747","DOI":"10.1073\/PNAS.1305066110\/SUPPL_FILE\/PNAS.201305066SI.PDF","volume":"110","author":"J Varadarajan","year":"2013","unstructured":"Varadarajan J, McWilliams MJ, Hughes SH (2013) Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations. Proc Natl Acad Sci U S A 110:14747\u201314752. https:\/\/doi.org\/10.1073\/PNAS.1305066110\/SUPPL_FILE\/PNAS.201305066SI.PDF","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3461_CR118","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.3390\/MD8122871","volume":"8","author":"TS Vo","year":"2010","unstructured":"Vo TS, Kim SK (2010) Potential anti-HIV agents from marine resources: an overview. Mar Drugs 8:2871. https:\/\/doi.org\/10.3390\/MD8122871","journal-title":"Mar Drugs"},{"key":"3461_CR119","unstructured":"V\u00f6lker P, Haza L von, W\u00f6ntz C, Zakharchuk D (2020) Raltegravir"},{"key":"3461_CR120","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S2055-6640(20)31150-X","volume":"1","author":"MA Wainberg","year":"2015","unstructured":"Wainberg MA, Han Y-S (2015a) HIV\u20131 resistance to dolutegravir: update and new insights. J Virus Erad 1:13\u201316. https:\/\/doi.org\/10.1016\/S2055-6640(20)31150-X","journal-title":"J Virus Erad"},{"key":"3461_CR121","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3389\/FPHAR.2015.00090\/BIBTEX","volume":"6","author":"MA Wainberg","year":"2015","unstructured":"Wainberg MA, Han YS (2015b) Will drug resistance against dolutegravir in initial therapy ever occur? Front Pharmacol 6:90. https:\/\/doi.org\/10.3389\/FPHAR.2015.00090\/BIBTEX","journal-title":"Front Pharmacol"},{"key":"3461_CR122","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3389\/FCIMB.2019.00362\/BIBTEX","volume":"9","author":"C Wallet","year":"2019","unstructured":"Wallet C, De Rovere M, Van Assche J et al (2019) Microglial cells: the main HIV-1 reservoir in the brain. Front Cell Infect Microbiol 9:362. https:\/\/doi.org\/10.3389\/FCIMB.2019.00362\/BIBTEX","journal-title":"Front Cell Infect Microbiol"},{"key":"3461_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/J.PARINT.2021.102432","volume":"85","author":"D Waluyo","year":"2021","unstructured":"Waluyo D, Prabandari EE, Pramisandi A et al (2021) Exploring natural microbial resources for the discovery of anti-malarial compounds. Parasitol Int 85:102432. https:\/\/doi.org\/10.1016\/J.PARINT.2021.102432","journal-title":"Parasitol Int"},{"key":"3461_CR124","first-page":"111","volume":"27","author":"AM Wensing","year":"2019","unstructured":"Wensing AM, Calvez V, Ceccherini-Silberstein F et al (2019) 2019 update of the drug resistance mutations in HIV-1. Top Antivir Med 27:111","journal-title":"Top Antivir Med"},{"key":"3461_CR125","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02406-20","author":"KL White","year":"2021","unstructured":"White KL, Osman N, Cuadra-Foy E et al (2021) Long dissociation of bictegravir from HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.02406-20","journal-title":"Antimicrob Agents Chemother"},{"key":"3461_CR126","doi-asserted-by":"publisher","DOI":"10.1101\/2021.02.23.432583","author":"CHH Xuan","year":"2021","unstructured":"Xuan CHH, Kion LN, Rahman T et al (2021) Regression QSAR models for predicting HIV-1 integrase inhibitors. BioRxiv. https:\/\/doi.org\/10.1101\/2021.02.23.432583","journal-title":"BioRxiv"},{"key":"3461_CR127","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1021\/CI300541C\/SUPPL_FILE\/CI300541C_SI_001.PDF","volume":"53","author":"W Xue","year":"2013","unstructured":"Xue W, Jin X, Ning L et al (2013) Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis. J Chem Inf Model 53:210\u2013222. https:\/\/doi.org\/10.1021\/CI300541C\/SUPPL_FILE\/CI300541C_SI_001.PDF","journal-title":"J Chem Inf Model"},{"key":"3461_CR128","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0090799","volume":"9","author":"W Xue","year":"2014","unstructured":"Xue W, Liu H, Yao X (2014) Molecular modeling study on the allosteric inhibition mechanism of HIV-1 integrase by LEDGF\/p75 binding site inhibitors. PLoS ONE 9:e90799. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0090799","journal-title":"PLoS ONE"},{"key":"3461_CR129","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1358\/DOT.2019.55.11.3068796","volume":"55","author":"J Zeuli","year":"2019","unstructured":"Zeuli J, Rizza S, Bhatia R, Temesgen Z (2019) Bictegravir, a novel integrase inhibitor for the treatment of HIV infection. Drugs Today 55:669\u2013682. https:\/\/doi.org\/10.1358\/DOT.2019.55.11.3068796","journal-title":"Drugs Today"},{"key":"3461_CR130","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5559338","author":"J Zhou","year":"2021","unstructured":"Zhou J, Hao J, Peng L et al (2021) Classification and design of HIV-1 integrase inhibitors based on machine learning. Comput Math Methods Med. https:\/\/doi.org\/10.1155\/2021\/5559338","journal-title":"Comput Math Methods Med"}],"container-title":["Archives of Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-023-03461-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00203-023-03461-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-023-03461-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T01:01:36Z","timestamp":1744160496000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00203-023-03461-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,26]]},"references-count":130,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["3461"],"URL":"https:\/\/doi.org\/10.1007\/s00203-023-03461-8","relation":{},"ISSN":["0302-8933","1432-072X"],"issn-type":[{"value":"0302-8933","type":"print"},{"value":"1432-072X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,26]]},"assertion":[{"value":"2 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"142"}}